48 related articles for article (PubMed ID: 32541630)
1. Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Deng GC; Lv Y; Yan H; Sun DC; Qu TT; Pan YT; Han QL; Dai GH
BMC Cancer; 2021 Nov; 21(1):1227. PubMed ID: 34781928
[TBL] [Abstract][Full Text] [Related]
2. Development of a nomogram to predict survival in advanced biliary tract cancer.
Imaoka H; Ikeda M; Nomura S; Morizane C; Okusaka T; Ozaka M; Shimizu S; Yamazaki K; Okano N; Sugimori K; Shirakawa H; Mizuno N; Satoi S; Yamaguchi H; Sugimoto R; Gotoh K; Sano K; Asagi A; Nakamura K; Ueno M
Sci Rep; 2023 Dec; 13(1):21548. PubMed ID: 38057434
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience.
Vijayvergia N; Dotan E; Devarajan K; Hatahet K; Rahman F; Ricco J; Lewis B; Gupta S; Cohen SJ
J Geriatr Oncol; 2015 Nov; 6(6):454-61. PubMed ID: 26296909
[TBL] [Abstract][Full Text] [Related]
4. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients.
Macchini M; Peretti U; Orsi G; Zanon S; Mazza E; Valente MM; Tamburrino D; Belfiori G; Rossi G; Testoni SGG; Passoni P; Doglioni C; Cascinu S; Reni M
Cancer Chemother Pharmacol; 2021 Jan; 87(1):95-101. PubMed ID: 33159215
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T; Makiyama A; Shimokawa M; Otsuka T; Shinohara Y; Koga F; Ueda Y; Nakazawa J; Otsu S; Komori A; Arima S; Fukahori M; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Ureshino N; Mizuta T; Mitsugi K; Akashi K; Baba E
Sci Rep; 2023 May; 13(1):8815. PubMed ID: 37258608
[TBL] [Abstract][Full Text] [Related]
6. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Komori A; Otsu S; Shimokawa M; Otsuka T; Koga F; Ueda Y; Nakazawa J; Arima S; Fukahori M; Okabe Y; Makiyama A; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Ureshino N; Mizuta T; Shirakawa T; Mitsugi K
Int J Clin Oncol; 2023 Aug; 28(8):1073-1081. PubMed ID: 37209158
[TBL] [Abstract][Full Text] [Related]
7. Establishment of the diagnostic and prognostic nomograms for pancreatic cancer with bone metastasis.
Liu Z; Liu H; Wang D
Sci Rep; 2022 Oct; 12(1):18085. PubMed ID: 36302941
[TBL] [Abstract][Full Text] [Related]
8. Multimodality therapy in metastatic pancreas cancer with a
Sutton TL; Grossberg A; Ey F; O'Reilly EM; Sheppard BC
Cancer Biol Ther; 2021 Dec; 22(10-12):532-536. PubMed ID: 34696697
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic pancreatic adenocarcinoma: a review.
Thota R; Pauff JM; Berlin JD
Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
[TBL] [Abstract][Full Text] [Related]
10. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.
Goldstein D; Von Hoff DD; Chiorean EG; Reni M; Tabernero J; Ramanathan RK; Botteman M; Aly A; Margunato-Debay S; Lu B; Louis CU; McGovern D; Lee CK
Pancreas; 2020 Jul; 49(6):744-750. PubMed ID: 32541630
[TBL] [Abstract][Full Text] [Related]
11. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
12. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
[TBL] [Abstract][Full Text] [Related]
14. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
